Loading…
Genelux Corporation is projected to rise to $3.51 by 2027, a +19% move from its current price of $2.94. GNLX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $2.87 | $2.94 | $3.02 | +0.03% |
| Aug 5 | $2.84 | $2.94 | $3.05 | +0.07% |
| Aug 6 | $2.82 | $2.94 | $3.07 | +0.10% |
| Aug 7 | $2.80 | $2.94 | $3.09 | +0.13% |
| Aug 8 | $2.79 | $2.94 | $3.11 | +0.17% |
| Aug 9 | $2.77 | $2.95 | $3.13 | +0.20% |
| Aug 10 | $2.76 | $2.95 | $3.15 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.76 | $2.95 | $3.15 | +0.23% |
| Week 2 | $2.69 | $2.95 | $3.24 | +0.47% |
| Week 3 | $2.64 | $2.96 | $3.32 | +0.70% |
| Week 4 | $2.60 | $2.97 | $3.39 | +0.94% |
| Week 5 | $2.57 | $2.97 | $3.45 | +1.18% |
| Week 6 | $2.54 | $2.98 | $3.50 | +1.41% |
| Week 7 | $2.51 | $2.99 | $3.56 | +1.65% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for patients with aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
The company also offers CHOICE, a technology and discovery and development platform, and has developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. Genelux has a licensing agreement with Newsoara BioPharma Co. Ltd to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses.
Genelux was incorporated in 2001 and is headquartered in Westlake Village, California.
Genelux Corporation (GNLX) is a healthcare company focused on oncolytic viral immunotherapies. The current price is $2.96 per share, and the market capitalization is $132.73M, with a rank of 3982.
The 30-day outlook shows bullish sentiment in the near term, while the longer-term forecast projects meaningful upside from 2027 through 2050, with multi-year price appreciation indicated by the model’s year-by-year numbers.
A major floor 21.8% below — a decisive break under it would weaken the trend.
The nearest floor, 4.1% below — buyers have tended to step in here.
The nearest ceiling, 3.7% above — a clean break opens room to run.
A major ceiling 8.5% above — clearing it would confirm fresh momentum.
Key GNLX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GNLX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.94 | Buy | $2.94 | Sell |
| MA 10 | $2.93 | Buy | $2.93 | Buy |
| MA 20 | $2.94 | Buy | $2.93 | Buy |
| MA 50 | $2.95 | Sell | $2.92 | Buy |
| MA 100 | $2.81 | Buy | $2.97 | Sell |
| MA 200 | $3.54 | Sell | $3.19 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.48 | Neutral |
| Stoch RSI (14) | 55.17 | Neutral |
| CCI (20) | 4.88 | Neutral |
| Williams %R (14) | -47.83 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 1.03 | Buy |
| Bollinger %B (20,2) | 0.51 | Neutral |
| Stochastic %K (14) | 52.17 | Neutral |
| TRIX (15) | -0.02 | Sell |
| Awesome (5,34) | 0.00 | Buy |
| Ultimate (7,14,28) | 48.81 | Neutral |
| Momentum (10) | 0.07 | Buy |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 2.94 | Sell |
| ADX (14) | 6.10 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture shows a bullish bias, with RSI(14) at 50 and key moving averages near the current level: the SMA50 is $2.95 and the SMA200 is $3.61. Support is indicated at $2.82 and resistance at $3.03, suggesting a narrow trading range around the current level.
Over the last 30 days, the price range has been $2.55 to $3.44, and annualized volatility is 40%, reflecting notable near-term fluctuation within a tight price band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.30 | $2.94 | $3.94 | 0% | Neutral | |
| $2.82 | $3.51 | $4.60 | +19% | Neutral | |
| $3.34 | $4.26 | $5.78 | +45% | Bullish | |
| $3.58 | $4.67 | $6.51 | +59% | Bullish | |
| $3.71 | $4.92 | $7.02 | +67% | Bullish | |
| $4.85 | $6.54 | $9.52 | +123% | Bullish | |
| $5.80 | $7.95 | $11.78 | +170% | Bullish | |
| $6.31 | $8.77 | $13.21 | +198% | Bullish | |
| $7.05 | $9.94 | $15.19 | +238% | Bullish | |
| $7.20 | $10.29 | $15.94 | +250% | Bullish | |
| $12.34 | $18.72 | $30.73 | +537% | Bullish | |
| $20.86 | $35.00 | $62.53 | +10.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.30 | $2.94 | $3.61 | +0.00% |
| September 2026 | $2.54 | $3.00 | $3.63 | +2.09% |
| October 2026 | $2.55 | $3.03 | $3.71 | +0.98% |
| November 2026 | $2.63 | $3.14 | $3.87 | +3.71% |
| December 2026 | $2.65 | $3.18 | $3.94 | +1.05% |
Click any year to see its month-by-month GNLX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The GNLX price prediction for 2026 points to an average of $2.94 (low $2.30, high $3.94) — a potential gain of 0% on today's $2.94. Price action looks broadly range-bound.
In 2027, GNLX is projected to trade between $2.82 and $4.60, averaging $3.51 — a potential gain of +19% from today's $2.94. That is up +19% on the projected 2026 average. A consolidation phase looks the most probable path here.
Genelux Corporation's 2028 outlook centres on $4.26, within a $3.34 to $5.78 range. That is up +21% on the projected 2027 average. That marks a +45% change versus current levels. Momentum favours further upside here.
By 2029, GNLX could reach as high as $6.51, with a base case around $4.67 and support toward $3.58 — roughly +59% from $2.94. Buyers look set to stay in control over this stretch.
Expect GNLX to range from $3.71 to $7.02 through 2030. The $4.92 average target implies a +67% move from current prices. That is up +5% on the projected 2029 average. Momentum favours further upside here.
The GNLX price prediction for 2031 points to an average of $6.54 (low $4.85, high $9.52) — a potential gain of +123% on today's $2.94. Buyers look set to stay in control over this stretch.
In 2032, GNLX is projected to trade between $5.80 and $11.78, averaging $7.95 — a potential gain of +170% from today's $2.94. That is up +21% on the projected 2031 average. Momentum favours further upside here.
Genelux Corporation's 2033 outlook centres on $8.77, within a $6.31 to $13.21 range. That is up +10% on the projected 2032 average. That marks a +198% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, GNLX could reach as high as $15.19, with a base case around $9.94 and support toward $7.05 — roughly +238% from $2.94. Momentum favours further upside here.
Expect GNLX to range from $7.20 to $15.94 through 2035. The $10.29 average target implies a +250% move from current prices. That is up +4% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The GNLX price prediction for 2040 points to an average of $18.72 (low $12.34, high $30.73) — a potential gain of +537% on today's $2.94. Momentum favours further upside here.
In 2050, GNLX is projected to trade between $20.86 and $62.53, averaging $35.00 — a potential gain of +10.9x from today's $2.94. That is up +87% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in GNLX today (≈ 340.136054 GNLX) could be worth
$11,905
+$10,905 (+1091%) by 2050 · US Dollar
Based on the average projected GNLX price of $35 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GNLXwould be worth at today's price.
$1,000 invested in GNLX on Jul 31, 2025 (≈ 294.985242 GNLX) would be worth
$867.26
-$132.74 (-13.3%) today · 0.87× · US Dollar
Based on a GNLX entry price of $3.39 vs. today's $2.94.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.89 | $1,017.3 | +1.7% |
| 1 month ago | $2.9 | $1,013.79 | +1.4% |
| 3 months ago | $2.74 | $1,072.99 | +7.3% |
| 6 months ago | $2.73 | $1,076.92 | +7.7% |
| 1 year ago | $3.39 | $867.26 | -13.3% |
| All time (3.5y) ago | $6.15 | $478.05 | -52.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GNLX forecast.
Our base-case forecast reaches $5.90 around 2031.
Implied market cap at $5.90: $264.56M
The multi-year forecast points to substantial upside, with the 2030 average price projected at $4.95 and an implied ROI of 67.1% while maintaining a bullish sentiment for the decade.
Looking further out, the 2040 forecast shows an average of $17.78 with a 500.8% ROI and a bullish sentiment, and the 2050 forecast shows an average of $32.85 with a 1009.7% ROI and bullish sentiment.
These figures indicate strong long-run upside potential but remain estimates, not guarantees, and are subject to the typical uncertainties of clinical-stage biotech developments and market conditions.
Tap a question to reveal the answer.
The 2030 forecast lists an average price of $4.95 with a maximum of $6.94 and a minimum of $3.78, representing a projected ROI of 67.1% and bullish sentiment.
Long-term forecasts show bullish sentiment with an average price of $4.95 by 2030 and $32.85 by 2050, corresponding to ROI figures of 67.1% and 1009.7%, but these are estimates and not guarantees."
Yes. The forecast maximums include $11.14 in 2032 and $12.53 in 2033, indicating potential to exceed $10 in the early 2030s.
Current price: $2.96. Market cap: $132.73M.
2040 average is $17.78 with a maximum of $28.43 and ROI of 500.8%; 2050 average is $32.85 with a maximum of $56.84 and ROI of 1009.7%.
Genelux Corporation Community Discussion
0Share your Genelux Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.